Company Overview and News

1
Leap Therapeutics: An Updated Investment View

2018-09-21 seekingalpha
Today, we are sharing an investment idea on a small $7 developmental biotech concern named Leap Therapeutics.
LPTX MKGAF MKGAY MRK PFE

4
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

2018-09-20 zacks
The drug/biotech industry has regained its lost momentum in the past couple of months after a mild struggle in the initial part of the year, probably on broader market correction.
MRK MKGAF AZN MKGAY AZN PFE

9
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

2018-09-18 zacks
The demand for checkpoint inhibitors, especially those targeting PD-1 and PD-L1, has risen significantly in the past couple of years. It is estimated that their market will rise tremendously in the next four to five years. PD-1 and PD-L1 are proteins present on the surface of cancer cells
MKGAF AZN MKGAY AZN MDPEB MDP PFE

4
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

2018-09-14 zacks
This week Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda was in the limelight as it gained EU approval as a combination therapy for the first-line treatment of advanced lung cancer. AstraZeneca (AZN - Free Report) gained FDA approval for Lumoxiti, its treatment for hairy cell leukemia (“HCL”), a rare type of blood cancer. The regulatory agency however rejected Glaxo’s (GSK - Free Report) application for label expansion of its asthma drug, Nucala for a new indication – COPD.
MKGAF AZN CY MKGAY AZN PFE

46
Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

2018-09-13 seekingalpha
Share price of Foamix Pharmaceuticals (FOMX) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candidate is indicated in the treatment of moderate-to-severe acne. The trial is reported to have successfully met both primary and secondary endpoints.
MKGAF OPK GILD INCY KMPH GLPG ACRX IMNP MKGAY NVS ABBV FMI PFE ABBV FOMX

2
Your Cancer Highlight: A Pfizer-Merck KGaA Collab Bears Fruit In The Competitive Kidney Cancer Market

2018-09-13 seekingalpha - 1
The renal cell cancer space has been highly competitive, with substantial disruption coming in just the past few years.
MKGAF EXEL MKGAY PFE

4
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

2018-09-12 zacks
Pfizer, Inc. (PFE - Free Report) announced that a combination of its cancer drugs, Bavencio and Inlyta, significantly improved progression-free-survival (“PFS”) in a pivotal late-stage study. The phase III JAVELIN Renal 101 study evaluated the Bavencio/Inlyta combination against Pfizer’s older kidney cancer drug Sutent for first-line treatment of advanced renal cell carcinoma, the most common form of kidney cancer.
MKGAF AZN MKGAY AZN PFE

 
Pfizer, Merck Combination Therapy Shows Significant Improvement in Phase III

2018-09-11 biospace
Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma. It is characterized by cytoplasmic clearing and a pattern of small branching blood vessels.
MKGAF MKGAY

 
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer

2018-09-11 channelnewsasia
FRANKFURT: Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer's Inlyta drug in a late-stage study.
MKGAF MKGAY

 
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer

2018-09-11 reuters
FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.
MKGAF MKGAY

 
Definiens Embarks on Digital Pathology Collaboration with Merck's Exploratory and Clinical Development Programs

2018-09-10 accesswire
MUNICH, GERMANY / ACCESSWIRE / September 10, 2018 / Definiens AG, the tissue phenomics company, focused on the development and application of tissue based biomedical digital image analysis, data visualization, data mining solutions and data analysis, today announced that it has entered into a multi-year digital partnership agreement with Merck KGaA, the vibrant science and technology company, to support Merck's exploratory and clinical development programs using Definiens TissuePhenomics ™ solutions for quantification of biomarkers including immuno-profiling.
MKGAF MKGAY

3
Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS

2018-09-06 globenewswire
Mechelen, Belgium, 6 September 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its business highlights and financial results for the first half of 2018, prepared in accordance with the IAS 34 Interim Financial Reporting as adopted by the European Union. Furthermore, the Company provides it updated outlook for the full year 2018.
MKGAF MKGAY TMO GHDX

38
CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

2018-09-04 globenewswire
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- In a release issued earlier today by Ziopharm Oncology, Inc. (Nasdaq:ZIOP), please note the Company's upcoming annual meeting of stockholders is being held Sept. 18 rather than Sept. 8 as originally issued. The corrected release follows:
ZIOP MKGAF EGRX XON MKGAY PCRX PRTK ESPR

38
Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisling Capital, Nominated to Board of Directors

2018-09-04 globenewswire
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that its Board of Directors has nominated Scott Braunstein, M.D., an Operating Partner at Aisling Capital, a leading healthcare investment firm, for election to the Board of Directors at the Company’s annual meeting of stockholders on Sept. 8.
ZIOP MKGAF EGRX XON MKGAY PCRX PRTK ESPR

1
Ziopharm Oncology Is An Attractive Buy For 2018

2018-09-01 seekingalpha - 1
Ziopharm Oncology is deploying its Sleeping Beauty T-cell platform to shorten manufacturing of third generation CD19 targeting CAR-T cells in leukemia/lymphoma indication.
ZIOP MKGAF MKGAY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 004741844